Abstract
Introduction
Intratumoral and intertumoral heterogeneities are well recognized at molecular, cellular, and tissue scales [1] [2] [3] [4] [5] [6] . This is clearly evident in the imaging characteristics of glioblastoma multiforme, which typically include regions of high and low contrast enhancement as well as high and low interstitial edema and cell density. Several recent molecular studies have clearly demonstrated that there is also significant genetic variation among cells in different tumors and even in different regions of the same tumor [3] [4] [5] . In one study, for example, samples from spatially separated sites within glioblastoma multiforme (GBM) tumors found that multiple molecular subtypes were present in all of the examined tumors [3] . It is clear that this molecular heterogeneity may significantly limit efforts to personalize cancer treatment based on the use of molecular profiling to identify druggable targets [7] [8] [9] . However, there has, thus far, been little effort to relate the spatial heterogeneity observed in clinical imaging with the genetic heterogeneity found in molecular studies.
Temporal and spatial cellular heterogeneities are typically ascribed to clonal evolution generated by accumulating random mutations in cancer cell populations [3, 10, 11] . However, Darwinian dynamics are ultimately governed by the interactions of local environmental selection forces with cell phenotypes (not genotypes) [12, 13] . That is, while mutations may occur randomly, proliferation of that clone will proceed only if its corresponding phenotype is more fit than extant populations within the context of the local adaptive landscape. Because of this evolutionary triage of each heritable (i.e., genetic or epigenetic) event, we have proposed that intratumoral evolution is fundamentally linked to the regional variations in microenvironmental selection forces that ultimately determine the fitness of any genotype/phenotype [12] [13] [14] . We hypothesize that the Darwinian dynamics that link genetic changes with environmental conditions will permit the characterization of regional variations in the molecular properties of cancer cells with environmental conditions (such as blood flow, edema, and cell density) that can be determined with clinical imaging [15] .
Spatial heterogeneity in tumor characteristics is well recognized in cross-sectional clinical imaging (Figure 1 ). Many tumors exhibit significant regional differences in contrast enhancement along with variations in cellular density, water content, fibrosis, and necrosis. In clinical practice, this heterogeneity is typically described in nonquantitative terms. More recently, metrics [16, 17] of heterogeneity, such as Shannon entropy, have been developed and can be correlated with tumor molecular features [18] [19] [20] [21] and clinical outcomes [22] [23] [24] . However, metrics that assign a single value to heterogeneity tacitly assume that the tumor is "well mixed" and thus does not capture spatial distributions of specific tumor properties.
Here, our general goal is to develop a spatially explicit approach that identifies and quantifies specific subregions of the tumor based on clinical imaging metrics that may provide information about the underlying evolutionary dynamics. In this approach, we hypothesize that tumors will generally possess subregions with variable Darwinian dynamics, including environmental selection forces and phenotypic adaptation to those forces [15] . Our approach here generates radiologically defined "habitats" by spatially superimposing two different magnetic resonance imaging (MRI) sequences from the same tumor. Our goal in this initial work is to examine regional variations in perfusion/ extravasation based on T1 post-gadolinium images and interstitial edema/cell density determined by fluid attenuated inversion recovery (FLAIR) and T2 images. Clearly, a full characterization of Darwinian dynamics in intratumor habitats will require more extensive imaging probably from multiple modalities [e.g., positron emission tomography (PET), MRI, and computed tomography (CT)] or other MRI sequences (particularly apparent diffusion coefficient maps). Nevertheless, in this preliminary study, we ask the following questions: 1) Can GBMs be consistently divided into some small number of specific radiologically defined habitats based on combinations of images sensitive to blood flow and edema? 2) Does the distribution of these regions vary among tumors in different survival groups?
This work builds on prior studies using regional variations in MRI appearance to correlate with genetic and histologic tumor characteristics [25] [26] [27] [28] [29] . Here, we explicitly apply a novel ecological/ evolutionary perspective that allows clinical imaging characteristics to define regional variations in intratumoral Darwinian dynamics that govern intratumoral molecular heterogeneity. In the preliminary studies, we demonstrate that the distribution of these radiologically defined habitats can be correlated with clinical outcomes. 
Materials and Methods

Patient Information
A data set of 32 patients was collected between January and December 2012 from the publicly available The Cancer Genome Atlas (TCGA; http://cancerimagingarchive.net/) database for our preliminary study. Although the database contains more than 500 cases, full imaging sets were often not available. Patients were included if they 1) had complete MRI studies that included post-contrast T1-weighted, FLAIR, and T2-weighted sequences and 2) had clinical survival time. Patients were excluded if they had multiple tumors or if the tumor was too small to analyze (<2 cm in diameter). A subset of 66 cases (43 cases with less than 400 days survival and 23 cases with more than 400 days survival) satisfied these two conditions. In our initial analysis, we selected a balanced data set ( Figure 2 ) that included 16 cases each in group 1 (survival time below 400 days) and group 2 (survival time above 400 days), respectively. The latter 16 were arbitrarily chosen. All of the images had a 200 mm × 200 mm field of view and 5-mm slice thickness, with 256 × 256 or 512 × 512 acquisition matrices. To ensure uniform resolution of intravariation of each sequence, for each case, three channels were registered by bilinear interpolation. Since the enrolled patients were from multiple institutions, the studies were performed on a wide range of MRI units with some variations in technique.
Image Normalization
To enable consistent evaluations for all cases, the obtained MRI imaging data were processed by standardizing the intensity scales [30] . We employed the linear normalization on each volume. The voxels of each volume of the tumor region were independently normalized into the scale from 0 to 1. Thus, the normalization captured the local tumor variations of specific patients in the standard range.
Tumor Identification
For consistency, the regions of interest were segmented by manually drawn masks on the post-gadolinium T1-weighted images as shown in Figure 1 . Although automated tumor segmentation methods have been described [31, 32] , they can be unpredictably inaccurate and appeared to offer no advantage over manual segmentation in GBMs where tumor edges are characteristically well defined in T1 post-gadolinium sequences.
Histogram Analysis
For our initial analysis, we generated two-dimensional (2D) histograms ( Figures 3 and 4 ) of the cumulative voxel intensities for all tumors. To perform a cohort analysis, the frequencies were rescaled into a range [0,1] using the normalization described above. In the histograms, the y-axis represent the frequency with which a particular MRI sequence intensity (x-axis) was observed.
In addition, 3D histograms ( Figure 5 ) were used to visually observe variations in tumor heterogeneity. The x-and y-axes consisted of the available pairs of MRI modalities: post-gadolinium T1-weighted and FLAIR, post-gadolinium T1-weighted and T2-weighted, or FLAIR and T2-weighted. We used a joint histogram that considered the crossdistribution of each modality. For instance, considering the pair of post-gadolinium T1-weighted and FLAIR modalities, an aggregated histogram was formed by counting the joint intensity of each voxel (x i , x j ), where x i was denoted as the T1-weighted intensity signal and x j was the associated FLAIR intensity signal. The z-axis dimension represented the joint distribution of each voxel. The remaining combinations followed a similar process to obtain the 3D histogram representation.
Survival Time Criterion
The clinical survival time ( Figure 2 ) was defined as the number of days between the date of the initial pathologic diagnosis and the time to death obtained from the patient demographics in the TCGA database. We used the MRI imaging data that were obtained at the initial diagnosis, thus the possible influence of the following clinical therapy was not accounted for in our study. Since there was no explicit prior study suggesting the precise survival threshold for different survival groups, we chose to approximately follow the overall statistics in the study [33] , where a reported median value of survival time for malignant brain tumor was 12 to 14 months. In our study, the patient cohort was initially divided into two equal groups: group 1 (survival time < 400 days) and group 2 (survival time > 400 days), thus the criterion used here differs from that used in another study [34] , which defined long-term survival as more than 3 years (36 months); only 2% to 5% of patients were in this group. Figure 2 and Tables 1-3 summarize the clinical and molecular data. The group with survival time < 400 days were slightly older (mean age 62) and had more total mutations (n = 29) than the group with survival time > 400 days (mean age 60, total mutations = 25). Only limited 
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information was available on molecular subtype, although we note that recent investigations have shown that multiple subtypes are characteristically observed in each tumor [4] . The mean tumor diameter and overall volume was slightly greater in group 1, but the difference was not statistically significant. All patients were treated with radiation therapy, chemotherapy, and surgery, although details were not available.
Variations in Blood Flow and Cellular Density Figure 3 demonstrates variation in the normalized values of T1 post-gadolinium, T2-weighted, and FLAIR images in different survival groups. In the T1 post-gadolinium images, there are two populations that are roughly Gaussian distributions around high and low means. This suggests that GBMs are generally divided into regions of high and low contrast enhancement that we view as an approximate measure of blood flow. That is, while the dynamics leading to contrast enhancement includes blood flow and vascular integrity (extravasation), we assume in our bifurcated classification that the nonenhancing regions have poorer blood flow than the enhancing regions. Group 1 demonstrates a shift in the distribution of these enhancement regions from high to low.
The T2-weighted and FLAIR distributions suggest that group 1 tumors actually contain habitats that are either not present or rare within long-term survival tumors. For both FLAIR and T2-weighted histograms, the tumor volume is dominated by a single population, probably with one other smaller population leading to some asymmetry of the Gaussian distribution. In group 1, tumor set distribution is significantly more heterogeneous with at least three distinct regions.
Initial Spatial Analysis
Since the T1 post-gadolinium images were consistently divided into two regions, we used this as a starting point for combining sequences. All of the tumors were divided spatially into high and low enhancement regions using a normalized intensity of 0.26 as the dividing point. The threshold was found by fitting a Gaussian mixture model [35, 36] to a cumulative histogram of all T1 post-gadolinium images and finding where two classes intersected. After this spatial division, FLAIR values were projected onto the high and low enhancement groups. As shown in Figure 4 , this resulted in clear separation of the GBM images into five distinct radiologically defined combinations of contrast enhancement and interstitial edema. In the high enhancement (i.e., high T1 post-gadolinium) regions, there is a region with low FLAIR signal indicating cell density and interstitial edema comparable to normal brain tissue. However, a second habitat with higher FLAIR signal indicates that some tumor regions with high levels of enhancement have lower cell density and higher interstitial edema than normal tissue. Similarly, in the low enhancement regions of the tumor, one subregion shows very high FLAIR signal representing necrosis. However, two additional subregions each with less water and more apparent cellularity are also present. We interpret this to indicate the presence of viable cell populations that have adapted to local environmental conditions generated by low flow (e.g., hypoxia and acidosis).
Applying Spatial Analysis to Clinical Response
The two groups were analyzed using 3D graphs that plotted the relative frequency of regions with specific combinations of T1 post-gadolinium signal and either FLAIR or T2-weighted signal. As shown in Figure 4 , group 2 tumors typically consist of tumor habitats with high enhancement (i.e., >0.26) and relatively high cell density. Group 1 tumors had increased regions of low enhancement. Interestingly, while these often corresponded to high T2-weighted or FLAIR signal indicating necrosis, regions with low enhancement and relatively high cell density were frequently present.
Statistical Analysis and Clinical Survival Time Group Prediction
To test the predicative capability, a binary classification scheme (e.g., group 1 and group 2) was formulated. We used the machine learning classifier, support vector machines [38, 39] , to classify samples by using a Gaussian kernel function to project features into a high-dimensional space. Both leave-one-out and 10-fold crossvalidation schemes were used for performance evaluation. We determined the accuracy (81.25% for leave-one-out), specificity, and sensitivity values with results summarized in Table 4 . In addition, Table 3 . Distribution of Gene Mutations in Group 2.
Tumor ID CDKN2A EGFR PTEN PDGFRA TP53 CDK4 NF1 CDK6 Total X  2  8  0  9  0  10  X  X  2  11  X  X  2  12  0  13  X  X  2  14  X  X  2  15  X  1  16  X  1  Total  11  8  3  2  1  0  1  0  25 we show receiver operator curve (ROC) curves in Figure 6 , and the associated area under the curve values are also given.
Spatial Mapping
To examine the spatial clustering of habitats, we divided the combined imaging data sets into four arbitrary habitats-high and low blood flow and high and low cell density. These were then projected back onto the MRI studies. In detail, the nonparametric Otsu segmentation approach [40] was used for the intratumor segmentation. Given a modality, after setting the number of groups (two groups in our study) to be segmented, the Otsu algorithm iteratively searched for an optimal decision boundary until convergence. As shown in Figure 7 , habitats generally clustered into spatial groups after an intersection operation between two MRI modalities. The choice of modalities and mapping procedure can be varied according to the needs of the specific task. In short, as a tool for brain tumor heterogeneity analysis, the design of the spatial habitat concept gave rise to various opportunities for quantitative measurement (i.e., using these habitats to quantitatively observe tumor evolution progress). The detailed spatial relationships of the different groups will be the subject of future investigations.
Discussion
Multiple recent studies have demonstrated marked genetic heterogeneity between and within tumors. This is typically ascribed to clonal evolution driven by random mutations. However, genetic mutations simply represent one component ("a mechanism of inheritance") of Darwinian dynamics, which are ultimately governed by phenotypic heterogeneity and variations in environmental selection forces [12] . While genetic heterogeneity clearly poses a challenge to molecularly based targeted therapy, we hypothesize that these variations, rather than a stochastic process governed by random mutations, may represent predictable and reproducible outcomes from identifiable Darwinian dynamics.
In our model, intratumoral evolution is fundamentally governed by variations in environmental selection forces that are largely dependent on local blood flow. That is, while changes in cancer cells may be the result of random genetic or epigenetic events, clonal expansion of each new genotype is entirely dependent on its fitness Translational Oncology Vol. 7, No. 1, 2014 Imaging Habitats and Tumor Spatial Heterogeneity Zhou et al.
within the context of the local environment and the fitness of the competing tumor populations. Thus, the dominant cancer phenotype and genotype within each tumor region is largely determined by their ability to adapt to environmental conditions that are generally governed by blood flow including oxygen, glucose, H + , and serum growth factors. This suggests that only limited numbers of general adaptive strategies are necessary-i.e., evolving the capacity to survive and proliferate in hypoxia. However, the phenotypic expression of those strategies is a much larger set of possibilities and the genetic pathway to those phenotypes is likely very much larger [13] . Thus, the genetic variation among cancer cells could look chaotic even when the underlying evolutionary dynamics are fairly straightforward.
This connection between environmental selection forces and phenotypic adaptations/genetic heterogeneity provides a theoretical bridge between radiologic imaging and cellular evolution within tumors. Thus, we hypothesized that radiographic manifestation of blood flow and interstitial edema can identify and map distinctive variations in environmental selection forces ("habitats") within each tumor.
To evaluate the potential role of habitat variations in survival, we arbitrarily divided our study group into two groups based on survival time. Our results demonstrate that group 1 and group 2 GBMs have distinctly different patterns of vascularity and cellular density. As shown in Figure 4 , GBMs consistently divide into five MRI-defined combinations of blood flow and cellular density. At present, the underlying evolutionary dynamics cannot be determined unambiguously. Clearly, the expected patterns are high blood flow and high cell density and low blood flow with low cell density. The three additional regions of apparent mismatch between blood flow and cellular density will require further investigation. In general, it is likely that they represent two possible "ecologies": 1) cellular evolution. This could result in adaptive strategies that permit increased proliferation in regions of poor perfusion or increased utilization of substrate (because of Warburg physiology, for example) that increases glucose uptake and toxic acid production in regions that are well perfused. 2) Temporal variations in regional perfusion. This would result in cycles of normoxia and hypoxia so that the average perfusion results in greater or lesser cellularity than expected based on a single observation.
As shown in Figure 5 , we find that group 2 tumors are more homogeneous with a dominant habitat in which there is high blood flow and intermediate cell density. Group 1 tumors, however, contain relatively high volumes of low blood flow habitats that may have very low cell density indicating necrosis but often exhibit cell densities comparable to those seen in well-perfused regions.
This suggests a clear need to further investigate the reason(s) these habitats confer a poor prognosis. Multiple factors may be involved including poor perfusion and hypoxia, which may limit the effectiveness of chemotherapy or radiation therapy. Furthermore, hypoxiaadapted cells often exhibit more stem-like behavior with up-regulation of survival pathways that confers resistance to treatments.
Our study represents only a preliminary test of our underlying hypothesis and suffers from a number of limitations. Since this is an initial retrospective study using a publicly available database, clinical and imaging data were significantly limited. In particular, the absence of apparent diffusion coefficient maps did not permit estimates of regional variations in cell density. The MRI scans were performed on a wide range of imaging platforms with some variations in technique. The details of therapy were not available and so we cannot estimate the potential role of treatment variations in survival data. Furthermore, a large number of factors in addition to the tumor characteristics may influence survival. In particular, some of the short-term survivors may have died from complications of therapy. Finally, the analyzed cohort is relatively small and our results will need to be confirmed in larger retrospective and prospective studies.
Nevertheless, we show here that clinical imaging can be used to gain insight into the evolutionary dynamics within tumors. Our results suggest that combinations of sequences from standard MRI imaging can define spatially and physiologically distinct regions or habitats within the ecology of GBMs and that this may be useful as a patientspecific prognostic biomarker. Ultimately, many other combinations of imaging characteristics including other modalities such as FDG PET should be investigated and may provide greater information regarding intratumoral evolution. Finally, we note that changes in intratumoral habitats during therapy may provide useful information regarding response and the evolution of adaptive strategies.
